Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M4\aZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe0eFU2yqEQvF2= Mn7HOFjDqGh? MnO5Zoxw[2u|IEK3MW9JSy2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiClb33wZZJi[mynIITvJJRp[XRib3[gZoF{[WxibHX2[Yx{ NWmwbnFNOjZ|NUC1OlU>
NP69 NH:ySXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTNzLk[5xtEzNjV2IN88US=> NVvLe|dQOjZ{NUK1O|U>
NP460 M3HHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHRTWM2OD1{Mj64OeKyOS5zODFOwG0> MkHsNlYzPTJ3N{W=
C666-1 NXvQUYhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLzeHpKSzVyPUG5Mlk2yrF6LkmzJO69VQ>? NVr3emxLOjZ{NUK1O|U>
C666-1 MnzuR4VtdCCYaXHibYxqfHliQYPzZZk> NV:0OllVOTBiwsXN MVi0PEBp M4PYOWROW09? M17rPZNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIHPpd5Bt[XSrbh?= M2PlcFI3OjV{NUe1
C666-1  MlzpSpVv[3Srb36gRZN{[Xl? NFjz[ncyOCEEtV2= NGnOc|MzPCCq NHvKfnRFVVOR NXztTHR{[WO2aY\heIV{KHSqZTDwOVMheGG2aIfhfUwhfXC{ZXf1cIF1cW6pIIC1N{wheDJzIHHu[EBO\G1{ M2L1c|I3OjV{NUe1
C666-1 M2ftWmFxd3C2b4Ppd{BCe3OjeR?= M4XXN|ExKML3TR?= NV;vb|FKPDhxN{KgbC=> NFq0ZpJFVVOR Mlfxd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:gZ4l{eGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz NY[wSW8zOjZ{NUK1O|U>
A549 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T2OlI1KGh? M1zUOWlEPTB;MUeuOlghyrFiND61NkDPxE1? NWXXXphEOjZzMkWyN|A>
A549-NTC M{DUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y2Z|I1KGh? MlXGTWM2OD1zOT60NkDDuSBzLkm2JO69VQ>? NFG5No8zPjF{NUKzNC=>
A549-920 M1TKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXaZmUzPCCq MnXhTWM2OD1|Mz64OUDDuSB2Lki0JO69VQ>? MnXoNlYyOjV{M{C=
CRL-5908 NFHmTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKyOEBp NEH4O|ZKSzVyPUO4MlcyKMLzIEKuOFMh|ryP Mnv0NlYyOjV{M{C=
L6 NWTJc3pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm0[IEyOMLizszNxsA> MlnWNlQwPDhxN{KgbC=> M1;CXGROW09? NYH1dW97cW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w M4S4OFI2QDdzN{m0
C2C12 NHPa[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XXflExyqEQvF5CpC=> MkXuNlQwPDhxN{KgbC=> MkK4SG1UVw>? Mn\pbY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v NHuzPY8zPTh5MUe5OC=>
MCF-7  M3XUeGZ2dmO2aX;uJGF{e2G7 MmTMNVDDqM7:TR?= MV3EUXNQ Mmf0bY5pcWKrdIOgZ5lkdGmwIFSxJIFv\CCGaXPlduKh MnPjNlU4ODJ5MEO=
DU4475  M3i0U2Z2dmO2aX;uJGF{e2G7 NFTX[5U2NzFyL{KwJO69VQ>? MkXHNlTDqGh? MU\kc5dvemWpdXzheIV{KFSxY3GtNUBld3OnIHTldIVv\GWwdHz5 MoLWNlU2PDdzN{S=
SMMC-7721 MUXGeY5kfGmxbjDBd5NigQ>? MlrzNVAh|ryP NVnXNoVKPDhiaB?= NYLQVWkxTE2VTx?= MVHjZZV{\XNiRF7BJGRUSiCmYX3h[4U> NGC1e5IzPTV2NEO2NS=>
SMMC-7721 MmLCSpVv[3Srb36gRZN{[Xl? MlPtNVAh|ryP NYrWcGtmPDhiaB?= MXfEUXNQ NIrzeXpqdmS3Y3XzJJRp\SClaILvcYF1cW5vYn;1coQheHKxdHXpckBKTklzNjD0c{Bx[XK2aXHscJkhdG:lYXzpfoUhcW5idHjlJIN6fG:ybHHzceKh NF7ONFEzPTV2NEO2NS=>
SMMC-7721 NILaXI9HfW6ldHnvckBCe3OjeR?= MUmxNEDPxE1? NIXzWIY1QCCq NX7CWpZoTE2VTx?= M1nNUIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZtMgTWZPSjIEoH3SUmE> M3rjWFI2PTR2M{[x
SMMC-7721 MlvHSpVv[3Srb36gRZN{[Xl? MUixNEDPxE1? NXGzW3VmOzZiaB?= NHPkVpFFVVOR M2ThSoNifXOnczD0bIUh\WO2b4DpZ{BmgHC{ZYPzbY9vKG:oIFnGTVE3 M1HXVlI2PTR2M{[x
MCF-7 Mk\LSpVv[3Srb36gRZN{[Xl? NYXhXZpGOTEEoN88US=> MX[wMVI1KGh? NF\wTHJqdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG= NF76XJgzPTR6MkO3Ny=>
OVCAR10 MUTGeY5kfGmxbjDBd5NigQ>? NXTobZVMOTEEoN88US=> MXSyNYjDqA>? M2roNGROW09? MW\pcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz M2rHZ|I2PDJ4NUS4
NCI-H23 NGL5TllHfW6ldHnvckBCe3OjeR?= MXexNOKh|ryP NGrsZ20zOWkEoB?= NVf1dFloTE2VTx?= NUKzRoFucW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? NHX3bZMzPTR{NkW0PC=>
A2780 NUWzWXVZTnWwY4Tpc44hSXO|YYm= NFXIdJIyOMLizszN NWS0R2pJOjGqwrC= MWPEUXNQ NYL4b3ZicW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? NWPDdmxFOjV2Mk[1OFg>
NCI-H23 MlTZSpVv[3Srb36gRZN{[Xl? NIjNV3gyOMLizszN NH7LdJAzOWkEoB?= NVS4XnRDTE2VTx?= MX7k[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= M1zJZlI2PDJ4NUS4
A2780 Mnr4SpVv[3Srb36gRZN{[Xl? Mn;XNVDDqM7:TR?= MV6yNYjDqA>? NWTZUmJKTE2VTx?= NYHydYYz\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> Ml[4NlU1OjZ3NEi=
HCT116  MYrGeY5kfGmxbjDBd5NigQ>? M3;VelExKML3TR?= M{XUPVI1KGh? NHrOTndk[XW|ZYOgZUBxPTNvZHXw[Y5l\W62IITleJJieGyxaXSgS|Eu[XK{ZYP0JIlvKGSrcHzvbYQhUEOWMUG2JINtd26nczDEN{BidmRiREi= NGDHS5IzPTN6MEC1OS=>
MCF-10CA1a MWjGeY5kfGmxbjDBd5NigQ>? NYrQTIVIOTEEoN88US=> NFjqc3k1QCCq MVrEUXNQ MVzpcohq[mm2czDiZZNidCCrbo\hd4lwdiCjbnSgdoVlfWOnZDDUS2Yu|rJ|LXnu[JVk\WRiaX72ZZNqd25idH:gZoF{[WxibHX2[Yx{ NYnaW2h5OjV{NUe3Nlk>
MCF-10A1  MWTGeY5kfGmxbjDBd5NigQ>? MUmxNOKh|ryP NHjpVGYzPC92ODDo MVfEUXNQ MkfybY5pcWKrdIOgcYloemG2aX;uJI9nKG6xcn3hcEBjemWjc4Sg[ZBqfGinbHnhcOKh MXSyOVI2Pzd{OR?=
MCF-10CA1a MUPGeY5kfGmxbjDBd5NigQ>? MUOxNOKh|ryP MmjkNlQhcA>? MlXCSG1UVw>? NWPWfXNU\GWlcnXhd4V{KHSqZTDUS2Yu|rJ|LXnu[JVk\WRibWLORUBt\X[nbIOgc4ZOVVB{LNMgUW1RQSxiYX7kxsBqdnSnZ4LpcuKh|rMEoEO= NHztU|YzPTJ3N{eyPS=>
MCF-10CA1a MorESpVv[3Srb36gRZN{[Xl? MV6xNOKh|ryP MYKyOEBp MkHzSG1UVw>? MWPpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? M1HLZ|I2OjV5N{K5
SK-BR-7 M4fVS2Z2dmO2aX;uJGF{e2G7 NH;RV3cyOMLizszN NI[0W44zPCCq NFzDT3ZFVVOR Mm\YbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NGjo[3gzPTJ3N{eyPS=>
SUM102PT NHTzTmZHfW6ldHnvckBCe3OjeR?= M4\udVExyqEQvF2= M3KwRlI1KGh? Mnm2SG1UVw>? M4HoS4lvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= M2\OSlI2OjV5N{K5
RAW 264.7 MUjGeY5kfGmxbjDBd5NigQ>? NVO4NYNqOTEEoN88US=> NIX1ZWs{OCCvaX6= M3PJWpBz\X[nboTzJJRp\SCyNUOgdoVlfWO2aX;uJIlvKHKnc4DvcpNmKHSxIFzQVy=> NFryU3ozPTF5MkW0Oy=>
RAW 264.7 MmXMSpVv[3Srb36gRZN{[Xl? MonUNVDDqM7:TR?= MVizNEBucW5? MWLy[YR2[2W|IITo[UBNWFNvYYXncYVvfGWmIITo[UBPTi4QulKgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHjeIl3cXS7 NFHRZnEzPTF5MkW0Oy=>
RAW 264.7 MX7GeY5kfGmxbjDBd5NigQ>? MXSxNOKh|ryP MkHBN|AhdWmw NHnNeJdqdmirYnn0d{BNWFNvaX7keYNm\CCQTzDwdo9lfWO2aX;uxsA> NVLzdZdQOjVzN{K1OFc>
MCF7  NIHrVINE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX\0S2JQOi53INM1US=> NULzUHZIPSCm M3nKfWROW09? MXvz[Y5{cXSrenXzJG1ETjdidH:gVGFTWCCrbnjpZol1cW:w M3rZSlI2ODh3OUCy
MCF7  Ml3YSpVv[3Srb36gRZN{[Xl? NFrYe3YzNjViwsXN MnPROFghcA>? MoHVSG1UVw>? NVrYNWxG\GWlcnXhd4V{KHSqZTDoc41wdG:pb4XzJGRUSiC{ZYDhbZIh\nKncYXlcoNq\XN? MmDXNlUxQDV7MEK=
ACHN MmroR4VtdCCYaXHibYxqfHliQYPzZZk> MmDrNE42NTFyIN88US=> MlziNE03KGR? MXjEUXNQ NITBdotqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoPZNlUxPjd5OEe=
Caki-2 MlPTR4VtdCCYaXHibYxqfHliQYPzZZk> M4H1V|AvPS1zMDFOwG0> M4roNVAuPiCm M{OwVmROW09? NHz6Zo9qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFixSoYzPTB4N{e4Oy=>
A498 M1PZTmNmdGxiVnnhZoltcXS7IFHzd4F6 MmjvNE42NTFyIN88US=> NVvpNm1JOC14IHS= NV7Kfol2TE2VTx?= NX;hOnhRcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mo\oNlUxPjd5OEe=
115 MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnXoNE42NTFyIN88US=> Mm\TNE03KGR? NEC1eVRFVVOR Ml[wbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYSyOVA3Pzd6Nx?=
117 NGrxNVlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX:wMlUuOTBizszN NVT3bHQ{OC14IHS= MV7EUXNQ MnP6bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NV\tRY9EOjVyNke3PFc>
ACHN NFH3[oZHfW6ldHnvckBCe3OjeR?= NV30U2hGOC53L{GvOUDPxE1? NXj1OJBtPDhiaB?= MWHEUXNQ NIjnV5ht\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NHLRUIQzPTB4N{e4Oy=>
Caki-2 MkG0SpVv[3Srb36gRZN{[Xl? NV7VZ2pwOC53L{GvOUDPxE1? M2jBb|Q5KGh? NEn6e|NFVVOR M4\Qfoxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz MnX2NlUxPjd5OEe=
A498 M1:zNWZ2dmO2aX;uJGF{e2G7 MkXNNE42NzFxNTFOwG0> MmLWOFghcA>? NEXPT3hFVVOR NXrQUpNNdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= NXTkcmFDOjVyNke3PFc>
115 MYLGeY5kfGmxbjDBd5NigQ>? M1f5elAvPS9zL{Wg{txO NWjoS2k2PDhiaB?= NVPGTlF1TE2VTx?= NVHwTXJIdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= NGXDZ|czPTB4N{e4Oy=>
ACHN NH3CfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjhNGhPPSEQvF2= M3LuelQ5KGh? NXzS[3BzTE2VTx?= M2rDOolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> M16z[lI2ODZ5N{i3
Caki-2 M37HU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3BUFZkPSEQvF2= MXq0PEBp NVruV3dbTE2VTx?= MV7pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NEH4dmYzPTB4N{e4Oy=>
A498 NWfCTnVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjwOHNpPSEQvF2= M1LxSFQ5KGh? M4\jTGROW09? MnX0bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NWH2XFdqOjVyNke3PFc>
115 M1LHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3MOUDPxE1? NHK4foU1QCCq M4jWcmROW09? NVvwUpR3cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh M1u0dVI2ODZ5N{i3
ACHN M1vBSmZ2dmO2aX;uJGF{e2G7 NHzzZ3U2KM7:TR?= MmXvOFghcA>? MWrEUXNQ MWLpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NFj0bZYzPTB4N{e4Oy=>
Caki-2 NWHvPJRJTnWwY4Tpc44hSXO|YYm= Mn32OUDPxE1? NEG3[5k1QCCq M4OyZWROW09? NGPEPINqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg M4XMOFI2ODZ5N{i3
A498 NUm0cHhwTnWwY4Tpc44hSXO|YYm= MWi1JO69VQ>? MkThOFghcA>? NXLLOnJQTE2VTx?= MYrpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MXKyOVA3Pzd6Nx?=
115 NHzzN5BHfW6ldHnvckBCe3OjeR?= NGTrdGg2KM7:TR?= M2HCT|Q5KGh? M3TwfGROW09? M{fHOolv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= MVSyOVA3Pzd6Nx?=
MOLM-13 MorUSpVv[3Srb36gRZN{[Xl? MnLnOuKh|ryP NYjkS4xTOC16IHi= NFKxOJRFVVOR NX\O[IVscW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdFU{NCCPRF2yMEBxOjFiYX7kJIFk\XS7bHH0[YQheDV| MVqyOFg5PTB6Mh?=
MOLM-13 M1X0T2Z2dmO2aX;uJGF{e2G7 MXG2xsDPxE1? Mn3kOkBp M3niSmROW09? NYPpcXNW\W6qYX7j[ZMhfGinIHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhUDKEIHHu[EBp\WG2IIPoc4NsKHC{b4TlbY5{KEi|cEK3JIFv\CCKc4C5NC=> MmDSNlQ5QDVyOEK=
HepG2 NHLBTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWC3NkBp NHG5U2JFVVOR MnexTWM2OD1|NT64OkDDuSB{Lkmg{txO M3zPflI1QDh2OEC5
HepG2/As M{f1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL0fZE4OiCq MXvEUXNQ NV6wO|ZlUUN3ME22PE4yOyEEsTC5MlYh|ryP MnPVNlQ5QDR6MEm=
SMMC7721 M1noWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\Td21SPzJiaB?= NGTuSHdFVVOR M2fDbmlEPTB;M{GuNlghyrFiND6yJO69VQ>? NXfWdXRQOjR6OES4NFk>
SMMC7721/Ac NFjZdopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXM[5ZHPzJiaB?= NXTTeHBqTE2VTx?= MWTJR|UxRTV3LkKxJOKyKDVwMEOg{txO NWXMSHRqOjR6OES4NFk>
Huh-7 M1zkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq4O|IhcA>? NH3ZXYdFVVOR MojNTWM2OD1|Mz65OkDDuSB|Lkmg{txO NH7OZ40zPDh6NEiwPS=>
Hep3B MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:3NkBp MmSzSG1UVw>? NEDTN21KSzVyPUKwMlE5KMLzIEGuPFQh|ryP NXzZUYU5OjR6OES4NFk>
HepG2 MnT1RZBweHSxc3nzJGF{e2G7 NIT1OnlqdmS3Y3XzJIFxd3C2b4Ppdy=> MmfxNlQ5QDR6MEm=
SMMC7721 NXT5ZZpsSXCxcITvd4l{KEG|c3H5 M1\nO4lv\HWlZYOgZZBweHSxc3nz NFPZe3UzPDh6NEiwPS=>
Huh-7 NVLQV2s3SXCxcITvd4l{KEG|c3H5 NYHIUnE6cW6mdXPld{BieG:ydH;zbZM> MmLMNlQ5QDR6MEm=
Hep3B NU\iTWU3SXCxcITvd4l{KEG|c3H5 MV;pcoR2[2W|IHHwc5B1d3Orcx?= MVuyOFg5PDhyOR?=
U2OS  M4rLdGZ2dmO2aX;uJGF{e2G7 M4XxUFIxKM7:TR?= M1XFclI1KGh? M{DxdYlv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEKFTELBNUwhSkOOWF|CpIFv\EKFTGe= NGH5cVMzPDh4N{K1PS=>
AML2 MWjBdI9xfG:|aYOgRZN{[Xl? NFPIe2UzNzFyIN88US=> NXzSemVyOjRxNEigbC=> MUDpcoR2[2W|IHHwc5B1d3Orcx?= MnjPNlQ3PTl5NEm=
MOML13 NEjCSZRCeG:ydH;zbZMhSXO|YYm= MVeyM|ExKM7:TR?= Mmm1NlQwPDhiaB?= NYHGUJlycW6mdXPld{BieG:ydH;zbZM> NF7zeWozPDZ3OUe0PS=>
AML2 NV;abIg4TnWwY4Tpc44hSXO|YYm= Ml3VNVDPxE1? NVzZTmJMOi92IHi= MVHpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= Ml;MNlQ3PTl5NEm=
AML3 MoXVSpVv[3Srb36gRZN{[Xl? M4LWelEx|ryP NUnMV|M3Oi92IHi= NF3Mc|FqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> MlnoNlQ3PTl5NEm=
MOML13 NFT4UFRHfW6ldHnvckBCe3OjeR?= NX2zSlViOTEQvF2= M1HRR|IwPCCq MUPpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= MUeyOFY2QTd2OR?=
BeWo NX;aR4FSTnWwY4Tpc44hSXO|YYm= NXvwVIxlOzBiwsXN NX3zZ29ZOjRiaB?= MnjjbY5kemWjc3XzJJA2OyxiTXTtNkwheDJzIHHu[EBRfW2jIHH0JJRp\SCycn;0[YlvKGyndnXs M{T2VlI1PDl6MUW0
BeWo MnfqRZBweHSxc3nzJGF{e2G7 NGPob4w{OCEEtV2= MljUNlQhcA>? NG\IXHFqdmO{ZXHz[ZMh[XCxcITvd4l{ MXmyOFQ6QDF3NB?=
OCI NFPnXIJHfW6ldHnvckBCe3OjeR?= NIHlPY4yOCEQvF2= NF:ySI4zPCCq NUTlUHFSfXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u M1\xNlI1PDd|NU[y
MOLM NEDJS5lHfW6ldHnvckBCe3OjeR?= MY[xNEDPxE1? MVeyOEBp NHjabo12eHKnZ4XsZZRmeyC2aHWgV29EWy1zIHX4dJJme3Orb36= M13UZVI1PDd|NU[y
U2OS  M3LJdWZ2dmO2aX;uJGF{e2G7 M2HR[lIxKM7:TR?= MlPiNlQhcA>? M1vnS4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? NX7qRoNpOjR|Nk[wNFc>
RKO M{[wT2Z2dmO2aX;uJGF{e2G7 MlTzNlAh|ryP NH3MT24zPCCq Mn65bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>? NEjZRnMzPDN4NkCwOy=>
U2OS  NHrUSI9HfW6ldHnvckBCe3OjeR?= MWCyNEDPxE1? NWrSVlM6OjRiaB?= MXXpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= M1rrT|I1OzZ4MEC3
RKO M2XnRmZ2dmO2aX;uJGF{e2G7 M2W5W|IxKM7:TR?= M3z1TFI1KGh? MVXpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= NI\WVpIzPDN4NkCwOy=>
SMMC-7721  M2SxTmNmdGxiVnnhZoltcXS7IFHzd4F6 NEDyWnEyNjJ3LUKwJO69VQ>? NV[zRlh{OjRxNEivO|IhcA>? M2PWUmROW09? MVvpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= M2LselI1Ojh4M{Gy
HuH-7 M1HFWGNmdGxiVnnhZoltcXS7IFHzd4F6 M2jXWlEvOjVvMkCg{txO MoDVNlQwPDhxN{KgbC=> MVnEUXNQ M2fpbolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 MX:yOFI5PjNzMh?=
SMMC-7721  M1f6PGFxd3C2b4Ppd{BCe3OjeR?= NVHUd456OjBizszN MkK2OFghcA>? NUTpRZRRTE2VTx?= NH2yemRqdmS3Y3XzJIFxd3C2b4Ppdy=> NU\Rd5hOOjR{OE[zNVI>
HuH-7 NHSyS45CeG:ydH;zbZMhSXO|YYm= NEnydpczOCEQvF2= MYG0PEBp M{PWeGROW09? MnrWbY5lfWOnczDhdI9xfG:|aYO= M{f6ZVI1Ojh4M{Gy
SMMC-7721  Mo\PSpVv[3Srb36gRZN{[Xl? NWHFPVNXOTBizszN M1jTWlM3KGh? M12zdWROW09? MWrkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> M2izXVI1Ojh4M{Gy
HuH-7 MV3GeY5kfGmxbjDBd5NigQ>? NYrreHIxOTBizszN M2\CT|M3KGh? NYC5VW14TE2VTx?= Mme5[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> MUGyOFI5PjNzMh?=
AT2 M2\Vc2Z2dmO2aX;uJGF{e2G7 MnPFOU8yOCEQvF2= MWns[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? NFrScJozPDJ2MEKwNy=>
REH Mmm3SpVv[3Srb36gRZN{[Xl? NH\DR|M2NzFyIN88US=> M3PNTIxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li NEXyWnozPDJ2MEKwNy=>
UoCB6 NXPXWphkTnWwY4Tpc44hSXO|YYm= M1;PNlUwOTBizszN M{DS[4xm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li NX7RUVRzOjR{NECyNFM>
AT2 NHL1fGtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2L1ZVAuOjVizszN MlLTbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NEPEdmszPDJ2MEKwNy=>
REH M4DzdWNmdGxiVnnhZoltcXS7IFHzd4F6 NWLDZnNiOC1{NTFOwG0> NXyyNXlocW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mo[4NlQzPDB{MEO=
UoCB6 NVnKVVJbS2WubDDWbYFjcWyrdImgRZN{[Xl? NIS3boQxNTJ3IN88US=> NG\kbI1qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NFvk[nMzPDJ2MEKwNy=>
A2780 NEL3UnVHfW6ldHnvckBCe3OjeR?= NFXhNGI2NzFyL{KwJO69VQ>? NX65WGVkOjRiaB?= NH;JN|d2eHKnZ4XsZZRmeyCyNUOsJG1FVTJuIICyNUBidmRiRGK1JJBzd3SnaX6gcIV3\Wy|IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MXSyOFE{PjF2Nx?=
H460 MmjNSpVv[3Srb36gRZN{[Xl? M2myclUwOTBxMkCg{txO NGS0XWgzPCCq MkLWeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? MoXXNlQyOzZzNEe=
Lovo  NH\uWHVHfW6ldHnvckBCe3OjeR?= MUC1M|ExNzJyIN88US=> MnPkNlQhcA>? NVX5UWhDfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= MWiyOFE{PjF2Nx?=
A2780 MU\BdI9xfG:|aYOgRZN{[Xl? MVq1M|ExNzJyIN88US=> M1rmclI1KGh? MUDlcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> MXKyOFE{PjF2Nx?=
H460 MmjQRZBweHSxc3nzJGF{e2G7 NHHvXm82NzFyL{KwJO69VQ>? Mmi0NlQhcA>? MmnG[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> NHr0fWczPDF|NkG0Oy=>
Lovo  MlTTRZBweHSxc3nzJGF{e2G7 NWPOUGJjPS9zMD:yNEDPxE1? NVL4SW9JOjRiaB?= NHTBdWVmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? M1HlcVI1OTN4MUS3

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID